CLOZAPINE - SELECTIVE LABELING OF SITES RESEMBLING 5HT(6) SEROTONIN RECEPTORS MAY REFLECT PSYCHOACTIVE PROFILE

被引:62
作者
GLATT, CE
SNOWMAN, AM
SIBLEY, DR
SNYDER, SH
机构
[1] JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205
[2] JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205
[3] NINCDS,EXPTL THERAPEUT BRANCH,BETHESDA,MD 20892
关键词
D O I
10.1007/BF03401577
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Clozapine, the classic atypical neuroleptic, exerts therapeutic actions in schizophrenic patients unresponsive to most neuroleptics. Clozapine interacts with numerous neurotransmitter receptors, and selective actions at novel subtypes of dopamine and serotonin receptors have been proposed to explain clozapine's unique psychotropic effects. To identify sites with which clozapine preferentially interacts in a therapeutic setting, we have characterized dozapine binding to brain membranes. Materials and Methods: [H-3]Clozapine binding was examined in rat brain membranes as well as cloned-expressed 5-HT6 serotonin receptors. Results: [H-3]Clozapine binds with low nanomolar affinity to two distinct sires. One reflects muscarinic receptors consistent with the drug's anticholinergic actions. The drug competition profile of the second site most closely resembles 5HT(6) serotonin receptors, though serotonin itself displays low affinity. [H-3]Clozapine binding levels are similar in all brain regions examined with no concentration in the corpus striatum. Conclusions: Besides muscarinic receptors, clozapine primarily labels sites with properties resembling 5HT(6) serotonin receptors. If this is also the site with which clozapine principally interacts in intact human brain, it may account for the unique beneficial actions of clozapine and other atypical neuroleptics, and provide a molecular target for developing new, safer, and more effective agents.
引用
收藏
页码:398 / 406
页数:9
相关论文
共 40 条
[1]  
ADHAM N, 1991, MOL PHARMACOL, V41, P1
[2]  
ALBERT PR, 1990, J BIOL CHEM, V265, P5825
[3]  
AMLAIKY N, 1992, J BIOL CHEM, V267, P19761
[4]  
BERSANI G, 1986, CURR THER RES CLIN E, V40, P492
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]  
CHIODO LA, 1985, J NEUROSCI, V5, P2539
[7]   MOLECULAR-CLONING AND EXPRESSION OF THE GENE FOR A HUMAN D1 DOPAMINE RECEPTOR [J].
DEARRY, A ;
GINGRICH, JA ;
FALARDEAU, P ;
FREMEAU, RT ;
BATES, MD ;
CARON, MG .
NATURE, 1990, 347 (6288) :72-76
[8]  
FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538
[9]   THE GENOMIC CLONE G-21 WHICH RESEMBLES A BETA-ADRENERGIC-RECEPTOR SEQUENCE ENCODES THE 5-HT1A RECEPTOR [J].
FARGIN, A ;
RAYMOND, JR ;
LOHSE, MJ ;
KOBILKA, BK ;
CARON, MG ;
LEFKOWITZ, RJ .
NATURE, 1988, 335 (6188) :358-360
[10]   [3H]CLOZAPINE IS NOT A SUITABLE RADIOLIGAND FOR THE LABELING OF D-4 DOPAMINE-RECEPTORS IN POSTMORTEM HUMAN BRAIN [J].
FLAMEZ, A ;
DEBACKER, JP ;
WILCZAK, N ;
VAUQUELIN, G ;
DEKEYSER, J .
NEUROSCIENCE LETTERS, 1994, 175 (1-2) :17-20